Saturday 29 June 2024

J.P. Morgan Healthcare Conference

Reset all filters

Refine Search
Biosimilars
Celltrion presents strategic vision and growth plan
Celltrion presents strategic vision and growth plan   15 January 2024
Pharmaceutical
Amgen could compete with established leaders in obesity, says analyst
Amgen could compete with established leaders in obesity, says analyst   15 January 2024
Biotechnology
Ayvakit central to Blueprint’s 2024 plans
Blueprint Medicines Corporation has outlined its 2024 corporate strategy, promising accelerated revenue growth, sustainable research and development, and a clea   9 January 2024
Biotechnology
GSK to acquire Aiolos Bio and its biologic asthma candidate
GSK to acquire Aiolos Bio and its biologic asthma candidate   9 January 2024
Biotechnology
Merck expands oncology pipeline with Harpoon acquisition
Merck expands oncology pipeline with Harpoon acquisition   9 January 2024
Biotechnology
J&J wagers $2 billion to acquire Ambrx
J&J wagers $2 billion to acquire Ambrx   8 January 2024
Biotechnology
Mersana updates on expected milestones and JPM presentations
Mersana updates on expected milestones and JPM presentations   5 January 2024

Today's issue

Biotechnology
FDA slaps CRL on Rocket Pharma’s Kresladi
29 June 2024
Biotechnology
J&J moves Rybrevant into first-line setting with full EU approval
28 June 2024
Pharmaceutical
Latin America studies the adoption of regulatory reliance
28 June 2024
Pharmaceutical
EMA/CHMP June 2024 meeting highlights
28 June 2024
Pharmaceutical
550 jobs to go at EUROAPI as part of new Sanofi deal
28 June 2024
Biotechnology
Peter Flyn joins Arialys as president and CEO
28 June 2024
Biotechnology
Alzheimer’s drug Leqembi launched in China
28 June 2024

Company Spotlight

A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.




Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze